Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Free kappa light chains in multiple sclerosis spinal fluid.

R A Rudick, A Pallant, J M Bidlack

    Annals of Neurology
    |July 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Multiple Sclerosis Performance Test: validation of self-administered neuroperformance modules.

    European journal of neurology·2020
    Same author

    Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis.

    Multiple sclerosis (Houndmills, Basingstoke, England)·2015
    Same author

    Simple MRI metrics contribute to optimal care of the patient with multiple sclerosis.

    AJNR. American journal of neuroradiology·2014
    Same author

    Prescribing recommendations for interferon-Beta in multiple sclerosis.

    CNS drugs·2013
    Same author

    Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis.

    Neurology·2011
    Same author

    Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1a.

    Multiple sclerosis (Houndmills, Basingstoke, England)·2011

    Free kappa light chains in cerebrospinal fluid (CSF) are highly specific for multiple sclerosis (MS). Measurement of these free kappa chains shows significant diagnostic potential for MS, unlike free lambda chains or whole IgG.

    Area of Science:

    • Neuroimmunology
    • Clinical Chemistry

    Background:

    • Elevated immunoglobulin G (IgG) in cerebrospinal fluid (CSF) is a known marker for multiple sclerosis (MS).
    • The diagnostic significance of free immunoglobulin light chains in MS remains less understood.

    Purpose of the Study:

    • To quantify free kappa and lambda light chains and whole IgG in CSF of MS patients and controls.
    • To assess the diagnostic specificity of free kappa light chains for MS.

    Main Methods:

    • Sensitive and specific radioimmunoassays (RIAs) were employed for quantification.
    • Free kappa and lambda chains, and whole IgG concentrations were measured in CSF samples.

    Main Results:

    • Free kappa chains were detected in 84% of MS patients (33/39) but only 2.4% of controls (1/42).

    Related Experiment Videos

  • Free kappa chains were highly concentrated in the CSF of MS patients (71-120 fold).
  • Elevated free lambda chains and whole IgG showed no specificity for MS.

    • Conclusions:

    • Measurement of free kappa light chains in CSF is a highly specific biomarker for multiple sclerosis.
    • This assay demonstrates significant potential for improving MS diagnosis.